GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coya Therapeutics Inc (NAS:COYA) » Definitions » EPS (Diluted)

Coya Therapeutics (Coya Therapeutics) EPS (Diluted) : $-0.85 (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Coya Therapeutics EPS (Diluted)?

Coya Therapeutics's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.35. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.85.

Coya Therapeutics's EPS (Basic) for the three months ended in Mar. 2024 was $-0.35. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.85.

Coya Therapeutics's EPS without NRI for the three months ended in Mar. 2024 was $-0.35. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.80.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Coya Therapeutics EPS (Diluted) Historical Data

The historical data trend for Coya Therapeutics's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coya Therapeutics EPS (Diluted) Chart

Coya Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
- -0.74 -4.73 -0.79

Coya Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -0.28 -0.31 -0.34 0.15 -0.35

Competitive Comparison of Coya Therapeutics's EPS (Diluted)

For the Biotechnology subindustry, Coya Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coya Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coya Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Coya Therapeutics's PE Ratio falls into.



Coya Therapeutics EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Coya Therapeutics's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-7.988-0)/10.164
=-0.79

Coya Therapeutics's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-5.052-0)/14.458
=-0.35

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Coya Therapeutics  (NAS:COYA) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Coya Therapeutics EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Coya Therapeutics's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Coya Therapeutics (Coya Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
5850 San Felipe Street, Suite 500, Houston, TX, USA, 77057
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
Executives
Dieter Weinand director C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 01801
Fred Grossman officer: Chief Medical Officer C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Goldstein Dov A Md director
Adrian Hepner officer: Chief Medical Officer C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
David S Snyder officer: Chief Financial Officer ONE SCIENCE COURT, MADISON WI 53711
Hideki Garren director C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Anabella Villalobos director C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Howard Berman director, 10 percent owner, officer: Chief Executive Officer C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Ann Lee director C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Bertex Llc 10 percent owner 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057

Coya Therapeutics (Coya Therapeutics) Headlines

From GuruFocus